Cytek Biosciences, Inc. (CTKB), a leading innovator in cell analysis solutions, has announced the opening of its new innovation centre in Bellevue, Washington, representing the relocation of its former Seattle-area operations to a purpose-built facility designed to drive research and development advancements.

The newly renovated space will function as a central hub for innovation and technical experimentation, supporting the company’s vision of fostering collaboration and expediting product development. Situated in the thriving technology corridor of Bellevue, the location positions Cytek at the heart of a region renowned for its concentration of global technology enterprises.

The facility is equipped with advanced R&D laboratories, areas dedicated to instrument service training, customer demonstration spaces, and assembly and testing operations. Beyond its core technical functions, the site emphasizes employee well-being with modern amenities and collaborative work environments, reflecting Cytek’s commitment to a dynamic and innovative workplace culture.

“The Bellevue innovation centre marks a pivotal step in our strategic growth, enhancing our ability to develop and deliver groundbreaking cell analysis technologies,” stated Wenbin Jiang, PhD, Chief Executive Officer of Cytek Biosciences.

Regarding financial performance, CTKB shares have fluctuated between $3.09 and $6.18 over the past year. The stock closed Wednesday’s session at $4.65, up 0.65%, and continued its upward trajectory in after-hours trading, rising 3.01% to $4.79.

Also Read

Source link

Exit mobile version